Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 9/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | FNTB | P49356 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777543 | 1.00 | FNTA (0.60) | FNTAPGGT1BTDP1FNTBPOLB | |
| SCHEMBL6777546 | 0.82 | FNTA (0.55) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6782826 | 0.81 | FNTA (0.62) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6782824 | 0.81 | FNTA (0.62) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6776018 | 0.81 | FNTA (0.69) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6776021 | 0.81 | FNTA (0.69) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| Hydrochloric Acid SCHEMBL6777916 | 0.80 | FNTA (0.68) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6771871 | 0.78 | FNTA (0.63) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6771875 | 0.78 | FNTA (0.63) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL6772134 | 0.77 | FNTA (0.84) | FNTAPGGT1BTDP1FNTBTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | FNTA 20/4885PGGT1B 1021/4885TDP1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.